Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Yano

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Biological & Pharmaceutical Bulletin|May 28, 2025
Systemic mRNA Delivery into the Muscle of Duchenne Muscular Dystrophy Model Mice Using Alpha-Dystroglycan Binding Peptide Modified Lipid NanoparticlesEri Sasaki, Yuki Itaya, Yoko Endo-Takahashi, et al.
Oncology|April 7, 2026
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic PathwaysTakaya Ohno, Yuki Nakajima, Yuki Yoshikawa, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2023
Successful Treatment for Hepatoblastoma in Trisomy 18: A Case ReportKazuki Shirane, Ai Yoshimi, Takayuki Masuko, et al.
Oncology|December 31, 2023
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder InjuryKo Nakamura, Takaya Ohno, Teruo Inamoto, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial CarcinomaTeruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
In Vivo (Athens, Greece)|January 2, 2023
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder CancerAtsushi Ichihashi, Teruo Inamoto, Taizo Uchimoto, et al.
Urologic Oncology|March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinomaTaizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|July 23, 2021
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancerShunsuke Tsuzuki, Shota Kawano, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Biological & Pharmaceutical Bulletin|May 28, 2025
Systemic mRNA Delivery into the Muscle of Duchenne Muscular Dystrophy Model Mice Using Alpha-Dystroglycan Binding Peptide Modified Lipid NanoparticlesEri Sasaki, Yuki Itaya, Yoko Endo-Takahashi, et al.
Oncology|April 7, 2026
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic PathwaysTakaya Ohno, Yuki Nakajima, Yuki Yoshikawa, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2023
Successful Treatment for Hepatoblastoma in Trisomy 18: A Case ReportKazuki Shirane, Ai Yoshimi, Takayuki Masuko, et al.
Oncology|December 31, 2023
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder InjuryKo Nakamura, Takaya Ohno, Teruo Inamoto, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial CarcinomaTeruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
In Vivo (Athens, Greece)|January 2, 2023
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder CancerAtsushi Ichihashi, Teruo Inamoto, Taizo Uchimoto, et al.
Urologic Oncology|March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinomaTaizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|July 23, 2021
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancerShunsuke Tsuzuki, Shota Kawano, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
Pageof 4